ARCUTIS BIOTHERAPEUTICS INC
ARQTNASDAQ🏆 #1519 by market capUS Equity
$26.17▼ $0.04 (−0.17%)
Live1h▼ 0.2%
24h▼ 0.2%
7d▼ 3.0%
14d▼ 6.1%
30d▼ 3.5%
1y▲ 77.4%
🏦Market Cap
$3.27B
Small Cap
📈Revenue Growth (YoY)
+76.1%
High Growth
📊Gross Margin
91.1%
High
💵FCF Margin
—
⚖️P/S Ratio
7.0x
Fair
Otter Score
55
Weak
Trading Snapshot
- Day Range
- $25.77 – $26.48
- 52-Week Range
- $13.70 – $31.77
- Volume
- $4.78B
- Avg Volume
- $4.50B
- Shares Outstanding
- 125.1M
- Next Earnings
- Sep 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $470M
- Last Q Revenue
- $127M
- P/E Ratio
- 114.1
- P/S Ratio
- 7.0x
- EPS (TTM)
- $0.21
- Dividend Yield
- —
Why Investors Own ARQT
- ✓High-growth profile — revenue up +3.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$470M▲ +7.9% YoY
Gross Margin (TTM)
62.1%▲ +1.8% YoY
Operating Income (TTM)
$40M▲ +7.9% YoY
Free Cash Flow (TTM)
$45M▲ +7.9% YoY
About ARCUTIS BIOTHERAPEUTICS INC
A company profile for ARCUTIS BIOTHERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
55/100
Analyst Price Target
ⓘAverage Target
$25.66
▼ −1.9% Downside
High Target$28.17
Low Target$19.03
Based on 9 analysts
Latest News & Updates
🚀
Barron’s·2h ago
ARCUTIS BIOTHERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift ARQT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
ARCUTIS BIOTHERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.